Mbx biosciences, inc. common stockMBX.US Overview
MBX Overall Performance
MBX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
MBX Current Performance
1.27%
Mbx biosciences, inc. common stock
2.97%
Avg of Sector
1.52%
S&P500
MBX Key Information
MBX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
MBX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
MBX Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Price of MBX
MBX FAQ
When is MBX's latest earnings report released?
The most recent financial report for Mbx biosciences, inc. common stock (MBX) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MBX's short-term business performance and financial health. For the latest updates on MBX's earnings releases, visit this page regularly.
How much debt does MBX have?
As of the end of the reporting period, Mbx biosciences, inc. common stock (MBX) had total debt of 650K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does MBX have?
At the end of the period, Mbx biosciences, inc. common stock (MBX) held Total Cash and Cash Equivalents of 39.78M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is MBX's EPS continuing to grow?
According to the past four quarterly reports, Mbx biosciences, inc. common stock (MBX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of MBX?
Mbx biosciences, inc. common stock (MBX)'s Free Cash Flow (FCF) for the period is -18.14M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of MBX?
The latest valuation data shows Mbx biosciences, inc. common stock (MBX) has a Price-To-Earnings (PE) ratio of -4.86 and a Price/Earnings-To-Growth (PEG) ratio of 0.27. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.